Bristol-Myers Squibb - Top 10 Layoffs of 2010

Company: Bristol-Myers Squibb
Layoffs: 840
Scoop: After cutting out 7,000 employees last year, BMS barely made this year's list with its September layoffs. The company continues to prepare for the Plavix patent cliff, as generic counterparts take over a larger portion of the market. BMS was posting higher-than-expected profits when the layoffs occurred. But although the company's other drugs, including the antipsychotic Abilify continue to do well, Plavix's $6.5 billion is hard to replace. As Edward Jones analyst Linda Bannister said, "With the patent cliff all these companies are facing, they need to reduce costs as quickly as possible to navigate what is going to be a very challenging couple of years for the industry."

Bristol-Myers Squibb - Top 10 Layoffs of 2010

Suggested Articles

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.

Dupixent's number-one position in the eczema market will be tough to maintain as two dozen rivals line up to unseat it, Cantor Fitzgerald warns.